Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephropathy in Participants With Macroalbuminuria

NCT02410499 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Diabetic Nephropathy

Interventions

DRUG: MLN1202 Placebo
DRUG: MLN1202

Sponsor

Takeda